Novel Leukotriene D4 Receptor Antagonists and 5-Lipoxygenase Inhibitors: Implications in Human Disease

  • A. W. Ford-Hutchinson


The leukotrienes are a group of mediators derived from arachidonic acid through the action of the 5-lipoxygenase enzyme [1, 2]. The initial enzymic step involves insertion of molecular oxygen into arachidonic acid to produce the unstable intermediate 5-hydroperoxyeicosatetraenoic acid. This intermediate is converted in a dehydrase step by the same enzyme (5-lipoxygenase) to the 5,6-epoxide, leukotriene A4. The term leukotriene derives from
  1. 1.

    the fact that these compounds were first isolated out of leukocytes and

  2. 2.

    the presence of the triene conjugated system within the molecule which gives these compounds their characteristic ultraviolet spectra.



Polymorphonuclear Leukocyte Gastric Mucosal Blood Flow Pepsin Secretion Specific Receptor Site Natural Cytotoxic Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Samuelsson B (1982) The leukotrienes: an introduction. In: Samuelsson B, Paoletti R (eds) Adv in Prostaglandin, Thromboxane Leukotriene Res. Raven Press, New York, vol 9, pp 1–17Google Scholar
  2. 2.
    Samuelsson B (1983) Leukotrienes: A new class of mediators of immediate hypersensitivity reactions and inflammation. Adv in Prostaglandin Thromboxane Leukotriene Res. Raven Press, New York, vol 11, pp 1–13Google Scholar
  3. 3.
    Borgeat P. Samuelsson B (1979) Arachidonic acid metabolism in polymorphonuclear leukocytes: Effects of ionophore A23187. Proc Natl Acad Sei USA (76): 2148–2152CrossRefGoogle Scholar
  4. 4.
    Borgeat P, Samuelsson B (1979) Transformations of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of novel dihydroxyeicosatetraenoic acids. J Biol Chem 154: 2643–2646Google Scholar
  5. 5.
    Powell WS (1984) Properties of leukotriene B4 20-hydroxylase from polymorphonuclear leukocytes. J Biol Chem 258: 3082–3089Google Scholar
  6. 6.
    Camp RDR, Wollard PM, Mallet AJ, Fincham NJ, Ford-Hutchinson AW, Bray MA (1982) Neutrophil aggregating and chemokinetic properties of 5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid isolated from human leukocytes. Prostaglandins 23: 631–641PubMedCrossRefGoogle Scholar
  7. 7.
    Ford-Hutchinson AW, Bray MA, Doig MV, Shipley MF, Smith MJH (1980) Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286: 264–265PubMedCrossRefGoogle Scholar
  8. 8.
    Ford-Hutchinson AW (1985) Leukotrienes: Biological properties, evidence for specific receptor sites and evidence for the involvement of leukotrienes in pathological situations In: Lands WEM (ed) Biochemistry of Arachidonic Acid Metabolism. Boston, Nijhoff, pp. 269–285CrossRefGoogle Scholar
  9. 9.
    Goldman DW, Goetzl EJ (1982) Specific binding of leukotriene B4 to receptors on human polymorphonuclear leukocytes. J Exp Med 129: 1600–1604Google Scholar
  10. 10.
    Bray MA, Cunningham FM, Ford-Hutchinson AW, Smith MJH (1981) Leukotriene B4: A mediator of vascular permeability. Br J Pharmacol 72: 483–486PubMedGoogle Scholar
  11. 11.
    Wedmore CV, Williams TJ (1980) The control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature 284: 646–650Google Scholar
  12. 12.
    Rackham A, Ford-Hutchinson AW (1983) Inflammation and pain sensitivity: effects of leukotrienes D4, B4, and prostaglandin E1 in the rat paw. Prostaglandins 25: 193–203PubMedCrossRefGoogle Scholar
  13. 13.
    Payan DG, Missirian-Basteian A, Goetzl EJ (1984) Human T-lymphocyte subset specificity of the regulatory effects of leukotriene B4. Proc Natl Acad Sci USA 81: 3501–3505PubMedCrossRefGoogle Scholar
  14. 14.
    Rola Pleszczynski M, Borgeat P, Sirois P (1982) Leukotriene B4 induces human suppressor lymphocytes. Biochem Biophys Res Commun 108: 1531–1537CrossRefGoogle Scholar
  15. 15.
    Rola-Pleszczynski M, Gagnon L, Sirois P (1983) Leukotriene B4 augments human natural cytotoxic cell activity. Biochem Biophys Res Commun 113: 531–537PubMedCrossRefGoogle Scholar
  16. 16.
    Johnson HM, Torres BA (1984) Leukotrienes: positive signals for regulation of γ-interferon production. J Immunol 132: 413–416PubMedGoogle Scholar
  17. 17.
    Goodwin JS, Atluru D, Sierakowski S, Lianos EN (1986) Mechanism of action of glucocorticosteroids. Inhibition of T cell proliferation and Interleukin 2 production by hydrocortisone is reversed by leukotriene B4. J Clin Invest 77: 1244–1250PubMedCrossRefGoogle Scholar
  18. 18.
    Piper PJ (1984) Formation and action of leukotrienes: Physiol Rev 64: 744–761Google Scholar
  19. 19.
    Guindon Y, Girard Y, Maycock A, Ford-Hutchinson AW, Atkinson JG, Bélanger PC, Dallob A, DeSousa D, Dougherty H, Egan R, Goldenberg MM, Ham E, Fortin R, Hamel P, Hamel R, Lau CK, Leblanc Y, McFarlane CS, Piechuta H, Thérien M, Yoakim C, Rokach J (1984) L-651,392, A Novel, Potent, and Selective 5-Lipoxygenase Inhibitor. Adv in Prostaglandin, Thromboxane and Leukotriene Res (Eds B Samuelsson, R Paoletti, and PW Rumwell) Raven Press, New York, pp 554–557Google Scholar
  20. 20.
    Letts LG, McFarlane CS, Piechuta H, Ford-Hutchinson AW (1987) The effects of a 5-lipoxygenase inhibitor (L-651,392) and leukotriene D4 antagonist (L-649,923) in two animal models of immediate hypersensitivity. Adv in Prostaglandin, Thromboxane and Leukotriene Res (Eds. B Samuelsson, R Paoletti, and PW Rumwell) Raven Press, New York, pp 1007–1011Google Scholar
  21. 21.
    Garceau D, Ford-Hutchinson AW The role of leukotrienes in allergen-induced vascular permeability changes in the guinea-pig conjunctiva. Adv in Prostaglandin, Thromboxane and Leukotriene Res (Eds B Samuelsson, R Paoletti, and PW Rumwell) Raven Press, New York, pp 167–170Google Scholar
  22. 22.
    Jones TR, Guindon Y, Young R, Champion E, Charette L, DeHaven RN, Denis D, Ethier D, Ford-Hutchinson AW, Fortin R, Letts G, Masson P, Maycock A, McFarlane C, Piechuta H, Pong SS, Rokach J, Yoakim C (1986) L-648,051, Sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy) propylsulfonyl]-γ-oxo-benzenebutanoate: A leukotriene D4 receptor antagonist. Can J Physiol Pharmacol, 64: 1535–1542PubMedCrossRefGoogle Scholar
  23. 23.
    Jones TR, Young R, Champion E, Charette L, Denis D, Ford-Hutchinson AW, Frenette R, Gauthier J-Y, Guindon Y, Kakushima M, Masson P, McFarlane C, Piechuta H, Rokach J, Zamboni R (1986) L-649,923, sodium (βS*, γR*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-γ-hydroxy- (3-methyl-benzenebutanoate, a selective orally active leukotriene receptor antagonist. Can J Physiol Pharmacol 64: 1068–1075PubMedCrossRefGoogle Scholar
  24. 24.
    Barnes N, Piper PJ, Costello J (1987) The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man. J Allergy Clin Immunol 79: 816–821PubMedCrossRefGoogle Scholar
  25. 25.
    Goldenberg MM, Subers EM (1983) The effect of leukotriene D4 on the isolated stomach and colon of the rat. Life Sciences 33: 2121–2127PubMedCrossRefGoogle Scholar
  26. 26.
    Holme G, Brunet G, Masson P, Girard Y, Rokach J (1980) The activity of synthetic leukotriene C-l on guinea-pig trachea and ileum. Prostaglandins 20: 717–721PubMedCrossRefGoogle Scholar
  27. 27.
    Pendleton RG, Shepherd-Rose AJ, Stavorski JM (1986) Leukotriene effects upon the transgastric potential difference and pepsin secretion. Europ J Pharmacol 123: 29–30CrossRefGoogle Scholar
  28. 28.
    Pendleton RG, Stavorski JR (1986) Evidence for differing leukotriene receptors in gastric mucosa. Europ J Pharmacol 125: 297–299CrossRefGoogle Scholar
  29. 29.
    Peskar BM, Lange K, Hoppe U, Peskar BA (1986) Ethanol stimulates formation of leukotriene C4 in rat gastric mucosa. Prostaglandins 31: 283–293PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • A. W. Ford-Hutchinson

There are no affiliations available

Personalised recommendations